Fair points but I think you’ll find this delay is common amongst most listed co’s (including the big end of town). Don’t think this is specific to Cellmid.
At the end of the day Maria is devoting resources to increasing sales, not increasing shareholder value. I’m ok with that. One will eventually follow the other.
2018 - The Year of the BioTechs, page-671
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
